← Russell 3000 cross-section

ARQT Arcutis Biotherapeutics, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-05, not restated
Healthcare

Scale

Market cap
$3.1bn
Revenue TTM
$464m
Net income TTM
$28m
Free cash flow
$39m
Composite score
49.0
Sector rank
#1374

Valuation

P / E
109.5
EV / EBITDA
EV / sales
6.4
FCF yield
1.25%
Earnings yield vs 10-yr
-3.82pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
6.2%
EBITDA margin
ROE
12.9%
ROIC
40.8%
Revenue growth
76.1%

Insider activity, last 90 days

Net open-market
$-2.08m
Buyers
0
Sellers
6

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Below are the time periods in which we began to recognize product revenue, net of deductions, related to the launches of each of our products and indications: Other Revenue Other revenue recognized to date is derived primarily from upfront license fees and milestone payments received pursuant to the Sato Agreement and Huadong Agreement. We expect that any other revenue we generate pursuant to these agreements will fluctuate from period to period as a result of the timing of potential milestone achievements and any potential regulatory approvals within the respective Sato Territory and Huadong Territories. …Arcutis Biotherapeutics, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-05

Read the full passage →